Paclitaxel and aCD47 synergized to yield remarkable antitumor activity in mice bearing systemic NHL disease. (A) A schematic showing the treatment strategy of the systemic Raji models. Mice were treated with an injection of nab-paclitaxel (50 mg/kg) followed by 2 injections of aCD47 (7.5 mg/kg) each week for a total of 4 weeks. (B) Representative animal images showing the efficacy of the combination therapy in reducing tumor burden. (C) Growth of tumors derived from Raji cells through IV injection into RAG2^−/−γc^−/− mice. Tumor signals were determined by bioluminescence imaging; a combination of nab-paclitaxel and aCD47 stopped the disease progression when other groups of mice reached the endpoint. ***P < .001 (1-way ANOVA test). (D) Survival analysis of animals in panels B and C showing the combination therapy significantly prolonged the survival of the mice. ***P < .001 (log-rank (Mantel-Cox) test). (E) Body weight analysis of animals in panels B and C showing the combination therapy was well tolerated by the mice.